Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Common Equity: 2019-2025

Historic Common Equity for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to $1.6 billion.

  • Revolution Medicines' Common Equity rose 1.95% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 1.95%. This contributed to the annual value of $2.3 billion for FY2024, which is 24.04% up from last year.
  • As of Q3 2025, Revolution Medicines' Common Equity stood at $1.6 billion, which was down 14.39% from $1.9 billion recorded in Q2 2025.
  • Revolution Medicines' Common Equity's 5-year high stood at $2.3 billion during Q4 2024, with a 5-year trough of $498.8 million in Q2 2022.
  • Its 3-year average for Common Equity is $1.6 billion, with a median of $1.6 billion in 2024.
  • In the last 5 years, Revolution Medicines' Common Equity dropped by 27.18% in 2022 and then surged by 166.52% in 2023.
  • Quarterly analysis of 5 years shows Revolution Medicines' Common Equity stood at $602.6 million in 2021, then grew by 13.71% to $685.2 million in 2022, then soared by 166.52% to $1.8 billion in 2023, then rose by 24.04% to $2.3 billion in 2024, then increased by 1.95% to $1.6 billion in 2025.
  • Its last three reported values are $1.6 billion in Q3 2025, $1.9 billion for Q2 2025, and $2.1 billion during Q1 2025.